NCT04739761: A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 4
Drug Category: Therapeutic antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients with or without brain metastasis are eligible
Exclusions: Patients with neurologically unstable brain metastasis requiring local therapy or steroids; Patients with known or suspected leptomeningeal disease; Patients with untreated brain lesions greater than 2.0 cm in size; Patients with prior tucatinib (TukysaTM) exposure
https://ClinicalTrials.gov/show/NCT04739761

Comments are closed.

Up ↑